Management of hepatitis B: our practice and how it relates to the guidelines

Abstract

Seven drugs have been approved for the treatment of chronic hepatitis B. Antiviral treatment has been shown to be effective in suppressing hepatitis B virus replication, decreasing inflammation and fibrosis in the liver, and preventing progression of liver disease. However, current medications do not eradicate hepatitis B virus; therefore, a key question is which patients need to start treatment and which patients can be monitored. Professional societies have developed guidelines to assist physicians in recognition, diagnosis, and optimal management of patients with chronic hepatitis B. These guidelines suggest preferred approaches, and physicians are expected to exercise clinical judgment to determine the most appropriate management based on the circumstances of the individual patient. This article reviews recommendations in hepatitis B guidelines and the basis for those recommendations, and we discuss what we do in our practice to illustrate factors that may influence decisions regarding hepatitis B management.

Keywords: AASLD; AFP; ALT; APASL; American Association for the Study of Liver Diseases; Antiviral Therapy; Asian Pacific Association for the Study of the Liver; CHB; Chronic Hepatitis B; EASL; European Association for the Study of the Liver; HBV; HBeAg; HBsAg; HCC; Hepatitis B Guidelines; IFN; Management; NUC; PEG-IFN; ULN; alanine aminotransferase; anti-HBc; anti-HBe; chronic hepatitis B; hepatitis B core antibody; hepatitis B e antibody; hepatitis B e antigen; hepatitis B surface antigen; hepatitis B virus; hepatocellular carcinoma; interferon; nucleos(t)ide analogue; pegylated-interferon; upper limit of normal; α-fetoprotein.